Modulation of Indoleamine 2,3-Dioxygenase 1 During Inflammatory Bowel Disease Activity in Humans and Mice

Overview

Journal Int J Tryptophan Res

Publisher Sage Publications

Specialty Biochemistry

Date 2023 Feb 17

PMID 36798536

Authors

Elisa Proietti

Renske W M Pauwels

Annemarie C de Vries

Elena Orecchini

Claudia Volpi

Ciriana Orabona

Maikel P Peppelenbosch

Gwenny M Fuhler

Giada Mondanelli

Affiliations

Soon will be listed here.

Abstract

Background And Aims: Indoleamine 2,3 dioxygenase-1 (IDO1), a key enzyme in tryptophan metabolism, is strongly up-regulated both in human inflammatory bowel disease (IBD) and animal models of colitis, however its role in the pathogenesis is still controversial. In this study, we investigated IDO1 expression and activity in a mouse model of DSS-induced chronic colitis as well as in colon biopsies and sera from IBD patients.

Methods: Chronic colitis was induced in mice through the oral administration of dextran sodium sulfate (DSS), and IDO1 activity was induced by i.p. treatment with N-acetyl serotonin (NAS). IDO1 expression and catalytic activity (measured as Kyn/Trp ratio) was evaluated in sera and tissue samples collected from mice and 93 IBD patients under immunotherapy with Vedolizumab (VDZ) or Ustekinumab (UST).

Results: Strong up-regulation of IDO1 was found in colons of mice with acute colitis, which follows disease activity. Enhanced IDO1 activity by NAS treatment protects the intestinal mucosa during the recovery phase of chronic colitis. In IBD patients, IDO1 expression and activity correlate with the severity of mucosal inflammation with inflamed regions showing higher IDO1 expression compared to non-inflamed regions within the same patient. Endoscopic response to VDZ/UST treatment is associated with decreased expression of IDO1.

Conclusions: This is the first study demonstrating immunomodulatory activity of IDO1 in a chronic mouse model of DSS-induced colitis. As its expression and catalytic activity correlate with the grade of mucosal inflammation and treatment response, IDO1 could represent a promising biomarker for disease severity and treatment monitoring in IBD.

Citing Articles

Kynurenines as a Novel Target for the Treatment of Inflammatory Disorders.

Mor A, Tankiewicz-Kwedlo A, Ciwun M, Lewkowicz J, Pawlak D Cells. 2024; 13(15.

PMID: 39120289 PMC: 11311768. DOI: 10.3390/cells13151259.

Alterations in tryptophan metabolism and NAD biosynthesis within the microbiota-gut-brain axis in chronic intestinal inflammation.

Devereaux J, Robinson A, Stavely R, Davidson M, Dargahi N, Ephraim R Front Med (Lausanne). 2024; 11:1379335.

PMID: 39015786 PMC: 11250461. DOI: 10.3389/fmed.2024.1379335.

Cinnamic Acid, Perillic Acid, and Tryptophan Metabolites Differentially Regulate Ion Transport and Serotonin Metabolism and Signaling in the Mouse Ileum In Vitro.

Jiang L, Hao Y, Li Q, Dai Z Int J Mol Sci. 2024; 25(12).

PMID: 38928404 PMC: 11203607. DOI: 10.3390/ijms25126694.

Fat and proteolysis due to methionine, tryptophan, and niacin deficiency leads to alterations in gut microbiota and immune modulation in inflammatory bowel disease.

Hara T, Meng S, Motooka D, Sato H, Arao Y, Tsuji Y Cancer Sci. 2024; 115(7):2473-2485.

PMID: 38679799 PMC: 11247612. DOI: 10.1111/cas.16153.

Immediate administration of hTERT-MSCs-IDO1-EVs reduces hypoalbuminemia after spinal cord injury.

Amanollahi S, Bahrami A, Haghighitalab A, Shaterzadeh Yazdi H, Kazemi Mehrjerdi H Vet Res Forum. 2024; 15(1):27-34.

PMID: 38464608 PMC: 10921135. DOI: 10.30466/vrf.2023.2003942.3903.

References

Agus A, Planchais J, Sokol H . Gut Microbiota Regulation of Tryptophan Metabolism in Health and Disease. Cell Host Microbe. 2018; 23(6):716-724. DOI: 10.1016/j.chom.2018.05.003. View

Gurtner G, Newberry R, Schloemann S, McDonald K, Stenson W . Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice. Gastroenterology. 2004; 125(6):1762-73. DOI: 10.1053/j.gastro.2003.08.031. View

Zhou L, Chen H, Wen Q, Zhang Y . Indoleamine 2,3-dioxygenase expression in human inflammatory bowel disease. Eur J Gastroenterol Hepatol. 2012; 24(6):695-701. DOI: 10.1097/MEG.0b013e328351c1c2. View

Ferdinande L, Demetter P, Perez-Novo C, Waeytens A, Taildeman J, Rottiers I . Inflamed intestinal mucosa features a specific epithelial expression pattern of indoleamine 2,3-dioxygenase. Int J Immunopathol Pharmacol. 2008; 21(2):289-95. DOI: 10.1177/039463200802100205. View

Shin J, Lee Y, Shon W, Kim B, Jeon C, Cho J . Gut microorganisms and their metabolites modulate the severity of acute colitis in a tryptophan metabolism-dependent manner. Eur J Nutr. 2020; 59(8):3591-3601. DOI: 10.1007/s00394-020-02194-4. View

Sofia M, Ciorba M, Meckel K, Lim C, Guillemin G, Weber C . Tryptophan Metabolism through the Kynurenine Pathway is Associated with Endoscopic Inflammation in Ulcerative Colitis. Inflamm Bowel Dis. 2018; 24(7):1471-1480. PMC: 6196764. DOI: 10.1093/ibd/izy103. View

Metghalchi S, Ponnuswamy P, Simon T, Haddad Y, Laurans L, Clement M . Indoleamine 2,3-Dioxygenase Fine-Tunes Immune Homeostasis in Atherosclerosis and Colitis through Repression of Interleukin-10 Production. Cell Metab. 2015; 22(3):460-71. DOI: 10.1016/j.cmet.2015.07.004. View

Jasperson L, Bucher C, Panoskaltsis-Mortari A, Taylor P, Mellor A, Munn D . Indoleamine 2,3-dioxygenase is a critical regulator of acute graft-versus-host disease lethality. Blood. 2007; 111(6):3257-65. PMC: 2265461. DOI: 10.1182/blood-2007-06-096081. View

Mondanelli G, Iacono A, Carvalho A, Orabona C, Volpi C, Pallotta M . Amino acid metabolism as drug target in autoimmune diseases. Autoimmun Rev. 2019; 18(4):334-348. DOI: 10.1016/j.autrev.2019.02.004. View

10.

Hornyak L, Dobos N, Koncz G, Karanyi Z, Pall D, Szabo Z . The Role of Indoleamine-2,3-Dioxygenase in Cancer Development, Diagnostics, and Therapy. Front Immunol. 2018; 9:151. PMC: 5797779. DOI: 10.3389/fimmu.2018.00151. View

11.

Kiesler P, Fuss I, Strober W . Experimental Models of Inflammatory Bowel Diseases. Cell Mol Gastroenterol Hepatol. 2015; 1(2):154-170. PMC: 4435576. DOI: 10.1016/j.jcmgh.2015.01.006. View

12.

Shon W, Lee Y, Shin J, Choi E, Shin D . Severity of DSS-induced colitis is reduced in Ido1-deficient mice with down-regulation of TLR-MyD88-NF-kB transcriptional networks. Sci Rep. 2015; 5:17305. PMC: 4661522. DOI: 10.1038/srep17305. View

13.

Ciorba M, Bettonville E, McDonald K, Metz R, Prendergast G, Newberry R . Induction of IDO-1 by immunostimulatory DNA limits severity of experimental colitis. J Immunol. 2010; 184(7):3907-16. PMC: 2945286. DOI: 10.4049/jimmunol.0900291. View

14.

Szigethy E, McLafferty L, Goyal A . Inflammatory bowel disease. Child Adolesc Psychiatr Clin N Am. 2010; 19(2):301-18, ix. DOI: 10.1016/j.chc.2010.01.007. View

15.

Ahmed O, Farid A, Elamir A . Dual role of melatonin as an anti-colitis and anti-extra intestinal alterations against acetic acid-induced colitis model in rats. Sci Rep. 2022; 12(1):6344. PMC: 9012815. DOI: 10.1038/s41598-022-10400-y. View

16.

Pallotta M, Orabona C, Volpi C, Vacca C, Belladonna M, Bianchi R . Indoleamine 2,3-dioxygenase is a signaling protein in long-term tolerance by dendritic cells. Nat Immunol. 2011; 12(9):870-8. DOI: 10.1038/ni.2077. View

17.

Ala M . Tryptophan metabolites modulate inflammatory bowel disease and colorectal cancer by affecting immune system. Int Rev Immunol. 2021; 41(3):326-345. DOI: 10.1080/08830185.2021.1954638. View

18.

Gupta N, Thaker A, Kanuri N, Riehl T, Rowley C, Stenson W . Serum analysis of tryptophan catabolism pathway: correlation with Crohn's disease activity. Inflamm Bowel Dis. 2011; 18(7):1214-20. PMC: 3235239. DOI: 10.1002/ibd.21849. View

19.

Cherayil B . Indoleamine 2,3-dioxygenase in intestinal immunity and inflammation. Inflamm Bowel Dis. 2009; 15(9):1391-6. DOI: 10.1002/ibd.20910. View

20.

Anderson G, Maes M . Gut Dysbiosis Dysregulates Central and Systemic Homeostasis via Suboptimal Mitochondrial Function: Assessment, Treatment and Classification Implications. Curr Top Med Chem. 2020; 20(7):524-539. DOI: 10.2174/1568026620666200131094445. View